Key Points

• Optimal medical therapy for patients with Heart Failure with Reduced Ejection Fraction (HFrEF) compromises of renin-angiotensin-aldosterone-system inhibitors that often cause hyperkalemia.
• If hyperkalemia cannot be mitigated with alternative methods, dose reductions, which compromise the effect of the optimal therapies, are often employed.
• Patirometer, which binds to potassium in exchange for calcium, was shown to help mitigate hyperkalemia in patients with HFrEF on RAAS-i.

Continue reading →